Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multidrug resistant infections

- PMLiVE

China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

China secures a place at the forefront of innovative medicine

AstraZeneca AZ

AZ’s Imfinzi plus tremelimumab combo misses again

Drug missed endpoint in small cell lung cancer trial

- PMLiVE

EU grants approval for Venclyxto/Gazyvaro combo in CLL

Chemotherapy-free option for previously-untreated patients

- PMLiVE

Potential universal flu vaccine shows efficacy in clinical trial

Candidate will now move forward into late-stage testing

AstraZeneca AZ

AZ’s comeback drug cediranib stumbles in phase 3 trial

Failed to improve on platinum-based chemotherapy

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

AstraZeneca AZ

AstraZeneca’s Imfinzi fails first-line bladder cancer test

Unable to improve overall survival in advanced metastatic bladder cancer

- PMLiVE

Allergan and Editas claim a CRISPR first in inherited blindness study

Partners are first to use CRISPR to edit cells inside the body

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

AbbVie says Allergan takeover delayed by FTC verdict

Merger now likely to complete in second quarter rather than first

- PMLiVE

AbbVie/Allergan merger faces renewed public opposition despite divestments

Consumer groups and public interest organisations raise new concerns

AstraZeneca AZ

AZ revenues rise, but it says coronavirus could hit 2020

Product sales up 12% to $23.57bn for the full-year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links